Antiplatelet and anticoagulant therapy after intracerebral hemorrhage

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Management of patients with an indication for long-term oral antithrombotic therapy who have an intracerebral hemorrhage (ICH) presents a therapeutic dilemma. Should antithrombotic therapy be resumed, and if so, when, using what agent, and for whom? There is no consensus for answers to these questions. In the absence of randomized trials, management of antithrombotic therapy after ICH is based on a combination of observational data, pathophysiologic concepts, and decision analysis. At the heart of the decision is an assessment of the individual patient's risk of thromboembolism off antithrombotic therapy versus risk of ICH recurrence on antithrombotic therapy.

Original languageEnglish
Pages (from-to)329-345
Number of pages17
JournalNeurologic Clinics
Issue number2
StatePublished - May 1 2015


  • Anticoagulation
  • Antiplatelet therapy
  • Atrial fibrillation
  • Intracerebral hemorrhage
  • Prosthetic heart valve
  • Venous thromboembolism


Dive into the research topics of 'Antiplatelet and anticoagulant therapy after intracerebral hemorrhage'. Together they form a unique fingerprint.

Cite this